Pancreatic Cancer

Tangential Versus Segmental Portomesenteric Venous Resection in Pancreatic Cancer Surgery: Insights from a Global Cohort Study

By MedXY 10/31/2026

This international multicenter study shows no significant difference in surgical complications or survival between tangential and segmental portomesenteric venous resections during pancreatoduodenectomy for pancreatic cancer with limited vein involvement.

Clinical Updates Gastroenterology Oncology

Targeting Mevalonate Biosynthesis: A Novel Strategy Against Gemcitabine-resistant Pancreatic Cancer

By MedXY 10/31/2026

This article explores how acquired resistance to gemcitabine in pancreatic cancer leads to metabolic reprogramming that creates a vulnerability in the mevalonate pathway, offering a promising therapeutic target.

Clinical Updates Oncology

KRAS Mutations in Duodenal Lavage Fluid After Secretin Stimulation: A Novel Biomarker for Early Detection of Pancreatic Cancer

By MedXY 10/29/2026

Emerging evidence demonstrates that KRAS mutation analysis in secretin-stimulated duodenal lavage fluid offers a minimally invasive and sensitive approach for early detection of resectable pancreatic ductal adenocarcinoma, outperforming traditional serum markers.

General Surgery news Oncology

Temporary Portal Vein Bypass in Pancreatectomy: Enhancing Safety in Complex Pancreatic Cancer Surgery

By MedXY 10/28/2026

Temporary mesoportal and mesocaval portal vein bypasses are effective surgical strategies in pancreatectomy with portal vein resection, offering comparable perioperative outcomes and facilitating safe resection of advanced pancreatic tumors.

Gastroenterology news Oncology

Targeting IMPDH2-Induced Guanine Nucleotide Depletion to Enhance KRAS Inhibition in Pancreatic Cancer

By MedXY 10/17/2026

An integrated genomic and pharmacologic analysis identifies IMPDH2 as a key vulnerability in KRAS-mutant pancreatic cancer, showing that irreversible guanine nucleotide depletion potentiates KRAS-targeted therapies and offers a novel combinational treatment avenue.

Gastroenterology news Oncology

MTFP1 and Metabolic Reprogramming: Unlocking New Targets in Pancreatic Cancer Liver Metastasis

By MedXY 10/14/2026

MTFP1 promotes pancreatic ductal adenocarcinoma liver metastasis by enhancing mitochondrial oxidative phosphorylation via the ROS/PI3K/AKT/c-MYC/SLC1A5 axis, revealing a promising therapeutic target to reverse tumor immune suppression and reduce metastatic colonization.

General Surgery news Oncology

Assessing the Learning Curve of Robotic Left-Sided Pancreatectomy: Safety and Oncological Outcomes in a Multicenter International Study

By MedXY 09/21/2026

This multicenter study evaluates how the surgical learning phase impacts major complications and oncological quality in robotic left-sided pancreatectomy, demonstrating safe adoption with consistent morbidity and highlighting the need for ongoing vigilance in complex cases.

General Surgery news Oncology

Unveiling Hidden High-Risk Phenotypes in Resected Solid Pseudopapillary Tumors Using Anomaly-Detection Models

By MedXY 09/14/2026

This study employs interpretable anomaly-detection algorithms to identify high-risk phenotypes in resected solid pseudopapillary pancreatic tumors, overcoming limitations of conventional survival models in ultra-rare cancer-specific deaths.

General Surgery Hematology-Oncology news

Circulating Exosomal microRNA Signature Enhances Preoperative Detection of Occult Liver Metastases in Pancreatic Cancer

By MedXY 09/07/2026

A multicenter study developed a robust exosomal microRNA-based model enabling preoperative detection of occult liver micrometastasis in pancreatic ductal adenocarcinoma, improving risk stratification and guiding treatment sequencing.

Gastroenterology news Oncology

Targeting the CA19-9 Glycan: A Promising CAR T Cell Therapy for Pancreatic and Gastrointestinal Cancers

By MedXY 08/30/2026

CAR T cells targeting the CA19-9 glycan show potent, specific anti-tumor activity in pancreatic and various gastrointestinal cancers, providing new avenues for immunotherapy of hard-to-treat solid tumors.

General Surgery news Oncology

Nationwide Evaluation of Robotic Distal Pancreatectomy for Malignancy: Safety, Outcomes, and Comparative Effectiveness in Japan

By MedXY 08/12/2026

This study analyzes nationwide data from Japan comparing robotic, laparoscopic, and open distal pancreatectomy for malignancy, highlighting robotic surgery’s safety and specific perioperative advantages, notably reduced blood loss and conversion rates, though benefits over laparoscopy remain limited.

Gastroenterology news Oncology

Targeting the IL-17/NGAL/NETs/ITGA5 Axis: A Novel Strategy to Overcome Immunosuppression and Fibroblast Reprogramming in Pancreatic Cancer

By MedXY 07/20/2026

This study unravels how tumour-derived NGAL induces NETs that reprogram fibroblast subtypes via ITGA5, promoting immunosuppression and tumour progression in pancreatic ductal adenocarcinoma, suggesting combinatorial therapies to enhance immunotherapy efficacy.

news Oncology

Multimodal C9-66 CAR-T Cell Therapy: A Promising Advance in Pancreatic Cancer Treatment

By MedXY 07/16/2026

This article reviews the development and preclinical evaluation of C9-66 CAR-T cell therapy targeting oncofetal chondroitin sulfate in pancreatic cancer, highlighting metabolic and microenvironmental optimizations that improve efficacy and durability.

Gastroenterology news Oncology

Fibrosis-Driven Activation of Schwann Cells in Pancreatic Cancer: Unraveling the Nuclear Mechanosensing Pathway

By MedXY 06/25/2026

Pancreatic fibrosis activates Schwann cells via nuclear mechanosensing, promoting a protumorigenic environment that enhances pancreatic cancer progression, offering novel microenvironment-targeted therapeutic insights.

Gastroenterology news Oncology

Pancreatic Cancer Risk During IPMN Surveillance: A SEER-Based Comparison

By MedXY 06/01/2026

A SEER-based study found IPMN surveillance patients have about 10 times higher pancreatic cancer risk than the general population, with highest risk in those with main duct dilation or obesity.

Gastroenterology news Oncology

Targeting Oncomucin-Driven Immunosuppression Improves KRAS G12D Inhibition in Pancreatic Cancer

By MedXY 05/28/2026

Oncomucins such as MUC4 and MUC16 help pancreatic cancer evade immunity through EGFR/UNC5B signaling. Targeting these mucins may enhance KRAS G12D inhibitor efficacy and reduce tumor burden.

Gastroenterology news Oncology

KRAS-Driven CLDN18.2 O-GlcNAcylation Promotes Pancreatic Cancer Progression and Therapy Resistance

By MedXY 05/16/2026

KRAS mutation and high glucose promote O-GlcNAcylation of CLDN18.2 in pancreatic cancer, pushing the protein off the cell membrane, boosting metastasis, and weakening CLDN18.2-targeted therapy. Low-dose MRTX1133 may restore sensitivity.

news Oncology Public Health

Age-Dependent Interplay of Modifiable Risk Factors and Genetic Risk in Pancreatic Cancer

By MedXY 05/15/2026

A UK Biobank study found that lifestyle-related pancreatic cancer risks were strongest in younger adults, especially those with high genetic risk, supporting early prevention efforts.

Gastroenterology news Oncology

CD276 Identified as Key Driver of Chemoresistance in Advanced Pancreatic Cancer

By MedXY 04/29/2026

Single-cell analysis reveals CD276/B7-H3 as a critical regulator of chemoresistance in pancreatic ductal adenocarcinoma, highlighting its dual role in promoting basal-like tumor states and immune evasion.

Gastroenterology Hematology-Oncology news

New EHR-Based Model PRIME Achieves 0.75 AUC in Predicting Pancreatic Cancer Risk Across 11 Million Patients

By MedXY 04/07/2026

Researchers developed PRIME, a parsimonious risk stratification model for pancreatic ductal adenocarcinoma using electronic health record data. Validated across US health systems and the UK Biobank, PRIME retained 19 predictors and achieved strong discrimination, enabling targeted early detection in high-risk populations.